ArticleHealth care science2024
Machine learning in neurological disorders: A multivariate LSTM and AdaBoost approach to Alzheimer's disease time series analysis.
Article in Health care science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Artificial intelligence risk stratification from dynamic digital subtraction angiography radiomics predicts pulmonary embolism and associates with clinical outcomes in deep vein thrombosis: A retrospective cohort study.Journal of vascular surgery. Venous and lymphatic disorders · 2026Article
- Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions.Acta pharmaceutica Sinica. B · 2025Review
- Machine learning in neurological disorders: A multivariate LSTM and AdaBoost approach to Alzheimer's disease time series analysis.Health care science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alzheimer's disease (AD) is a progressive brain disorder that impairs cognitive functions, behavior, and memory. Early detection is crucial as it can slow down the progression of AD. However, early diagnosis and monitoring of AD's advancement pose significant challenges due to the necessity for complex cognitive assessments and medical tests. Methods: This study introduces a data acquisition technique and a preprocessing pipeline, combined with multivariate long short-term memory (M-LSTM) and AdaBoost models. These models utilize biomarkers from cognitive assessments and neuroimaging scans to detect the progression of AD in patients, using The AD Prediction of Longitudinal Evolution challenge cohort from the Alzheimer's Disease Neuroimaging Initiative database. Results: The methodology proposed in this study significantly improved performance metrics. The testing accuracy reached 80% with the AdaBoost model, while the M-LSTM model achieved an accuracy of 82%. This represents a 20% increase in accuracy compared to a recent similar study. Discussion: The findings indicate that the multivariate model, specifically the M-LSTM, is more effective in identifying the progression of AD compared to the AdaBoost model and methodologies used in recent research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.